The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Open accessAbstract
Focusing on the Right Metabolite: A variety of human cancers, including acute leukemias and brain tumors, have mutations in the genes encoding isocitrate dehydrogenase 1 or 2 (IDH1, IDH2), which cause overproduction of a metabolite called 2-hydroxyglutarate (2HG). Losman et al. (p. 1621 , published online 7 February) show that the R - but not the S -enantiomer of 2HG can transform cells and that R -2HG mediates transformation at least in part through effects on protein modifying EglN prolyl hydroxylases. Importantly, the transforming activity of R -2HG was reversible, suggesting that therapeutic strategies focusing on inhibition of R -2HG production or inhibition of EglN prolyl hydroxylases merit further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A high level of R-2-HG is sufficient to cause leukemia to arise from hematopoietic cells by maintaining their dedifferentiation and proliferation activities116.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [116]
In the citing paper
“Interestingly, R-2HG is sufficient to promote cytokine independence and block differentiation of hematopoietic cells in vitro and these effects are fairly rapidly reversed upon R-2HG withdrawal (Losman et al., 2013; K. Yen, personal communication).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Losman et al., 2013
In the citing paper
“In various cellular settings, ectopic expression of a mutant IDH allele or treatment with exogenous D-2-HG is sufficient to induce DNA and histone hypermethylation and block cellular differentiation (Losman et al., 2013; Lu et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Losman et al., 2013
In the citing paper
“all suggesting that cellular reprogramming elicited by D-2-HG may play a prominent role in the pathogenesis of IDH-mutant tumours135-137.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [135]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S. N., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035
Regulation of the HIF-1α Level Is Essential for Hematopoietic Stem Cells
Takubo, K., Goda, N., Yamada, W., Iriuchishima, H., Ikeda, E., Kubota, Y., Shima, H., Johnson, R. S., Hirao, A., Suematsu, M., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.06.020 · Cited by 891
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
Choi, C., Ganji, S. K., DeBerardinis, R. J., Hatanpaa, K. J., Rakheja, D., Kovacs, Z., Yang, X.-L., Mashimo, T., Raisanen, J. M., Marin-Valencia, I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2682 · Cited by 839
Kitamura, T., Tange, T., Terasawa, T., Chiba, S., Kuwaki, T., Miyagawa, K., Piao, Y., Miyazono, K., Urabe, A., & Takaku, F. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041400219 · Cited by 784
Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727
Self-citationFalini, B., Nicoletti, I., Martelli, M. F., & Mecucci, C. (2006) · Blood · doi:10.1182/blood-2006-07-012252 · Cited by 575
Highly parallel identification of essential genes in cancer cells
Luo, B., Cheung, H. W., Subramanian, A., Sharifnia, T., Okamoto, M., Yang, X., Hinkle, G., Boehm, J. S., Beroukhim, R., Weir, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810485105 · Cited by 541
Self-citationIDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449
Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8
Wang, G. G., Calvo, K. R., Pasillas, M. P., Sykes, D. B., Häcker, H., & Kamps, M. P. (2006) · Nature Methods · doi:10.1038/nmeth865 · Cited by 408
A Multicolor Panel of Novel Lentiviral “Gene Ontology” (LeGO) Vectors for Functional Gene Analysis
Riecken, K., Bartsch, U., Stocking, C., & Fehse, B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.6 · Cited by 361
Modeling pO2 Distributions in the Bone Marrow Hematopoietic Compartment. I. Krogh's Model
Chow, D. C., Wenning, L. A., Miller, W. M., & Papoutsakis, E. T. (2001) · Biophysical Journal · doi:10.1016/s0006-3495(01)75732-3 · Cited by 253
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Popovici-Müller, J. V., Saunders, J. O., Salituro, F. G., Travins, J. M., Yan, S., Zhao, F., Größ, S., Dang, L., Yen, K. E., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300225h · Cited by 204
Kaelin, W. G. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010975 · Cited by 161
Self-citationForristal, C. E., Winkler, I. G., Nowlan, B., Barbier, V., Walkinshaw, G., & Lévesque, J.-P. (2012) · Blood · doi:10.1182/blood-2012-02-408419 · Cited by 133
The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion
Nguyen‐Khac, F., Della-Valle, V., Mauchauffé, M., Coniat, M. L., Ghysdael, J., Berger, R., & Bernard, O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120162297 · Cited by 85
Jensen, P. Ø., Mortensen, B. T., Hodgkiss, R. J., Iversen, P. O., Christensen, I. J., Helledie, N., & Larsen, J. K. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00183.x · Cited by 76
Ashton, J. M., Balys, M. M., Neering, S. J., Hassane, D. C., Cowley, G. S., Root, D. E., Miller, P. G., Ebert, B. L., McMurray, H. R., Land, H., et al. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.024 · Cited by 67
Self-citationAltitude, Radiation, and Mortality from Cancer and Heart Disease
Weinberg, C. R., Brown, K. G., & Hoel, D. G. (1987) · Radiation Research · doi:10.2307/3577265 · Cited by 62
Song, L.-P., Zhang, J., Wu, S.-F., Huang, Y., Zhao, Q., CAO, J. C., Wu, Y.-L., Wang, L., & Chen, G.-Q. (2007) · Oncogene · doi:10.1038/sj.onc.1210670 · Cited by 58
Liu, W., Guo, M., Xu, Y., Dao, L., Zhou, Z.-N., Wu, Y., Zhu, C., Kogan, S. C., & Chen, G. (2005) · Blood · doi:10.1182/blood-2005-03-1278 · Cited by 52
Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
Abdel-Wahab, O. I., Patel, J. L., & Levine, R. L. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.013 · Cited by 45
Correlation of Leukemia Mortality Rates With Altitude in the United States
Eckhoff, N. D., Shultis, J. K., Clack, R. W., & Ramer, E. R. (1974) · Health Physics · doi:10.1097/00004032-197410000-00006 · Cited by 16
Flagged first, then by citations
Cited by
Sorted by citations
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013
Cancer metabolism: looking forward
Martínez‐Reyes, I., & Chandel, N. S. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00378-6 · Cited by 1,877
Vyas, S., Zaganjor, E., & Haigis, M. C. (2016) · Cell · doi:10.1016/j.cell.2016.07.002 · Cited by 1,735
Metadata
- Authors
- Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Utah (US)
- University of Oulu (FI)
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2013-03-29
- Volume
- 339
- Issue
- 6127
- Pages
- 1621-1625
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3836459
- OpenAlex
- W2012588998
- Cited by
- 703
- References
- 32
- Citations by year
- 2026: 17 · 2025: 23 · 2024: 43 · 2023: 31 · 2022: 50 · 2021: 70 · 2020: 49 · 2019: 43 · 2018: 68 · 2017: 60 · 2016: 67 · 2015: 56 · 2014: 63 · 2013: 62
- FWCI
- 59.57
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- (R)-2-hydroxyglutarate, leukemogenesis, IDH1 R132H mutation, IDH2 mutation, isocitrate dehydrogenase, enantiomers, TET2, hematopoietic differentiation, reversible transformation, cancer cell models
- MeSH terms
- Cell Transformation, Neoplastic, Glutarates, Hematopoiesis, Humans, Isocitrate Dehydrogenase, Leukemia, Models, Biological, Procollagen-Proline Dioxygenase, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
